Home  |   Equities  |   Indexes  |   Commodities  |   Forex  |   News  |   Analysis  |   Top/Flop  |   Screening  |   Forums
May 25, 2012 02:41 pm US/Eastern
Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Arrowhead Research Corp    ARWR   US0427972098

Real time Streaming quotes -
 
Delayed Quote. Delayed Nasdaq - 05/25 01:25:00 pm
4.145 USD   -0.60%
05/22 ARROWHEAD RESEARCH CORP: Arrowhead Presents Data on DPC System at TIDES 20..
05/09 ARROWHEAD RESEARCH CORP: Arrowhead Presents Data on DPC System and Hepatit..
05/08 ARROWHEAD RESEARCH CORP: Arrowhead Reports Fiscal 2012 Second Quarter Fina..
SummaryQuotesChart AnalysisNewsCompanyForum 
 

Arrowhead Research Corp : Arrowhead to Report Fiscal 2012 First Quarter Financial Results

02/02/2012 | 08:24am

PRESS RELEASE
February 2, 2012

Investor Relations Contact:
Michael Levitan
The Trout Group, LLC
646-378-2920
ir@arrowres.com


PASADENA, Calif., February 2, 2012 - Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 first quarter ended December 31, 2011, on Thursday, February 9, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 877-317-6789 (toll free from the US and Canada), or 412-317-6789 (for international callers). Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com.

A replay of the webcast will be available approximately two hours after the conclusion of the call. The webcast archive will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until Thursday, February 16, 2012. The audio replay can be accessed by dialing 877-344-7529 (toll free from the US and Canada), or 412-317-0088 (for international callers) and entering Event ID 10009858.


About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company's lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and AdipotideTM, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic PolyConjugateTM (DPC), Liposomal Nanoparticle (LNP), and RONDELTM delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies.www.arrowheadresearch.com.

 
React to this article
Latest news on ARROWHEAD RESEARCH CORP
05/22 Arrowhead Presents Data on DPC System at TIDES 2012
05/09 Arrowhead Presents Data on DPC System and Hepatitis B Program at CLINAM 2012
05/08 Arrowhead Reports Fiscal 2012 Second Quarter Financial Results
04/11 Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Libra..
03/05 Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance an..
02/29 Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2a (EPAS1)
02/02 Arrowhead to Report Fiscal 2012 First Quarter Financial Results
01/04 Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial
2011 Leonardo Biosystems and NanoMedical Systems Sign Collaboration Deal for Manufact..
2011 Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations..
Advertisement
Chart
Duration : Period :
Arrowhead Research Corp Technical Analysis Chart | ARWR | US0427972098 | 4-Traders
Advertisement